As per Intent Market Research, the Lung Cancer Therapeutics Market was valued at USD 31.5 Billion in 2024-e and will surpass USD 62.8 Billion by 2030; growing at a CAGR of 12.2% during 2025-2030.
The lung cancer therapeutics market is experiencing robust growth, driven by the increasing prevalence of lung cancer, advancements in treatment modalities, and rising awareness about early diagnosis. Lung cancer, a leading cause of cancer-related deaths globally, has spurred significant investment in novel therapies, particularly targeted and immunotherapies, which promise better patient outcomes. With the continued integration of advanced drug classes and combination therapies, the market remains poised for sustained expansion.
Targeted Therapy Segment is Largest Owing to Precision Medicine Advancements
Targeted therapy leads the therapy type segment due to its ability to address specific genetic mutations such as EGFR, ALK, and ROS1 in lung cancer. These therapies are tailored to the molecular profile of tumors, ensuring better efficacy and fewer side effects compared to traditional methods. Drugs like Tagrisso (AstraZeneca) and Xalkori (Pfizer) have set benchmarks in this domain.
The rising adoption of companion diagnostics has further accelerated the uptake of targeted therapies. With continuous R&D efforts to identify new genetic targets, the segment is expected to maintain its dominance, providing personalized treatment solutions for patients worldwide.
Immune Checkpoint Inhibitors are Fastest Growing Owing to Expanding Applications
Within the drug class segment, immune checkpoint inhibitors are witnessing the fastest growth. These therapies, such as Keytruda (Merck) and Opdivo (Bristol-Myers Squibb), enhance the immune system's ability to attack cancer cells by targeting PD-1/PD-L1 or CTLA-4 pathways.
Their success in treating advanced and metastatic lung cancer, coupled with approvals for first-line treatment, has significantly expanded their market share. Ongoing clinical trials exploring new combinations and expanded indications are expected to further drive growth in this promising subsegment.
Non-Small Cell Lung Cancer (NSCLC) Segment is Largest Owing to High Prevalence
Non-small cell lung cancer (NSCLC) accounts for the largest share in the cancer type segment, representing approximately 85% of all lung cancer cases. The wide availability of treatment options, including chemotherapy, targeted therapy, and immunotherapy, has contributed to this dominance.
Recent advancements, such as the development of therapies targeting KRAS mutations, have further strengthened the treatment landscape for NSCLC. The introduction of combination regimens is expected to improve patient outcomes and sustain the segment's leadership in the market.
Online Pharmacies are Fastest Growing Owing to Rising Digital Adoption
Among distribution channels, online pharmacies are growing at the fastest rate, driven by the increasing adoption of digital healthcare platforms and the convenience they offer. These channels enable patients to access life-saving medications remotely, particularly in underserved regions.
The COVID-19 pandemic accelerated the shift toward online pharmacy usage. Enhanced regulatory frameworks and improved logistics networks are expected to sustain this growth, making online pharmacies an essential part of the lung cancer therapeutic ecosystem.
Asia-Pacific is the Fastest Growing Region Owing to Expanding Healthcare Access
Asia-Pacific is emerging as the fastest-growing region in the lung cancer therapeutics market. The region's growth is attributed to a rising incidence of lung cancer, increasing healthcare expenditure, and improved access to advanced treatments. Countries like China and India are investing heavily in healthcare infrastructure and cancer awareness campaigns.
Additionally, the availability of cost-effective generic drugs and the growing adoption of innovative therapies are contributing to the market's expansion in this region. Favorable government policies and initiatives to promote early cancer detection are further enhancing growth prospects.
Leading Companies and Competitive Landscape
The lung cancer therapeutics market is highly competitive, with leading companies such as AstraZeneca, Merck, Roche, and Bristol-Myers Squibb driving innovation. These players focus on expanding their portfolios through strategic collaborations, acquisitions, and investments in R&D. For instance, partnerships between pharmaceutical giants and biotechnology firms have accelerated the development of novel therapies.
The competitive landscape is characterized by the rapid approval of groundbreaking treatments and the introduction of biosimilars and generics, making therapies more accessible globally. With an emphasis on addressing unmet clinical needs, the market is set to witness sustained innovation and growth in the coming years.
Recent Developments:
- In late 2024, AstraZeneca and Daiichi Sankyo announced the global launch of Enhertu, a HER2-directed therapy targeting NSCLC.
- Merck received FDA approval in October 2024 for expanding Keytruda to include first-line treatment for metastatic NSCLC with high PD-L1 expression.
- Roche completed the acquisition of Blueprint Medicines' lung cancer pipeline in August 2024, enhancing its targeted therapy offerings.
- Pfizer and BioNTech announced a partnership in 2024 to develop mRNA-based personalized cancer vaccines for lung cancer.
- In November 2024, BMS launched a combination of Opdivo and chemotherapy for first-line treatment of advanced NSCLC in several European countries.
List of Leading Companies:
- AstraZeneca
- Pfizer Inc.
- Merck & Co., Inc.
- Roche Holding AG
- Bristol-Myers Squibb Company
- Novartis AG
- Eli Lilly and Company
- GlaxoSmithKline plc
- Bayer AG
- Sanofi
- AbbVie Inc.
- Johnson & Johnson
- Amgen Inc.
- Takeda Pharmaceutical Company Limited
- Boehringer Ingelheim
Report Scope:
Report Features |
Description |
Market Size (2024-e) |
USD 31.5 Billion |
Forecasted Value (2030) |
USD 62.8 Billion |
CAGR (2025 – 2030) |
12.2% |
Base Year for Estimation |
2024-e |
Historic Year |
2023 |
Forecast Period |
2025 – 2030 |
Report Coverage |
Market Forecast, Market Dynamics, Competitive Landscape, Recent Developments |
Segments Covered |
Lung Cancer Therapeutics Market By Therapy Type (Chemotherapy, Targeted Therapy, Immunotherapy, Radiation Therapy, Combination Therapy), By Drug Class (Tyrosine Kinase Inhibitors (TKIs), Immune Checkpoint Inhibitors, Anti-Angiogenesis Agents, Cytotoxic Agents), By Cancer Type (Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC)), By Distribution Channel (Hospitals, Retail Pharmacies, Online Pharmacies) |
Regional Analysis |
North America (US, Canada, Mexico), Europe (Germany, France, UK, Italy, Spain, and Rest of Europe), Asia-Pacific (China, Japan, South Korea, Australia, India, and Rest of Asia-Pacific), Latin America (Brazil, Argentina, and Rest of Latin America), Middle East & Africa (Saudi Arabia, UAE, Rest of Middle East & Africa) |
Major Companies |
AstraZeneca, Pfizer Inc., Merck & Co., Inc., Roche Holding AG, Bristol-Myers Squibb Company, Novartis AG, Eli Lilly and Company, GlaxoSmithKline plc, Bayer AG, Sanofi, AbbVie Inc., Johnson & Johnson, Amgen Inc., Takeda Pharmaceutical Company Limited, Boehringer Ingelheim |
Customization Scope |
Customization for segments, region/country-level will be provided. Moreover, additional customization can be done based on the requirements |
1. Introduction |
1.1. Market Definition |
1.2. Scope of the Study |
1.3. Research Assumptions |
1.4. Study Limitations |
2. Research Methodology |
2.1. Research Approach |
2.1.1. Top-Down Method |
2.1.2. Bottom-Up Method |
2.1.3. Factor Impact Analysis |
2.2. Insights & Data Collection Process |
2.2.1. Secondary Research |
2.2.2. Primary Research |
2.3. Data Mining Process |
2.3.1. Data Analysis |
2.3.2. Data Validation and Revalidation |
2.3.3. Data Triangulation |
3. Executive Summary |
3.1. Major Markets & Segments |
3.2. Highest Growing Regions and Respective Countries |
3.3. Impact of Growth Drivers & Inhibitors |
3.4. Regulatory Overview by Country |
4. Lung Cancer Therapeutics Market, by Therapy Type (Market Size & Forecast: USD Million, 2023 – 2030) |
4.1. Chemotherapy |
4.2. Targeted Therapy |
4.3. Immunotherapy |
4.4. Radiation Therapy |
4.5. Combination Therapy |
5. Lung Cancer Therapeutics Market, by Drug Class (Market Size & Forecast: USD Million, 2023 – 2030) |
5.1. Tyrosine Kinase Inhibitors (TKIs) |
5.2. Immune Checkpoint Inhibitors |
5.3. Anti-Angiogenesis Agents |
5.4. Cytotoxic Agents |
6. Lung Cancer Therapeutics Market, by Cancer Type (Market Size & Forecast: USD Million, 2023 – 2030) |
6.1. Non-Small Cell Lung Cancer (NSCLC) |
6.2. Small Cell Lung Cancer (SCLC) |
7. Lung Cancer Therapeutics Market, by Distribution Channel (Market Size & Forecast: USD Million, 2023 – 2030) |
7.1. Hospitals |
7.2. Retail Pharmacies |
7.3. Online Pharmacies |
8. Regional Analysis (Market Size & Forecast: USD Million, 2023 – 2030) |
8.1. Regional Overview |
8.2. North America |
8.2.1. Regional Trends & Growth Drivers |
8.2.2. Barriers & Challenges |
8.2.3. Opportunities |
8.2.4. Factor Impact Analysis |
8.2.5. Technology Trends |
8.2.6. North America Lung Cancer Therapeutics Market, by Therapy Type |
8.2.7. North America Lung Cancer Therapeutics Market, by Drug Class |
8.2.8. North America Lung Cancer Therapeutics Market, by Cancer Type |
8.2.9. North America Lung Cancer Therapeutics Market, by Distribution Channel |
8.2.10. By Country |
8.2.10.1. US |
8.2.10.1.1. US Lung Cancer Therapeutics Market, by Therapy Type |
8.2.10.1.2. US Lung Cancer Therapeutics Market, by Drug Class |
8.2.10.1.3. US Lung Cancer Therapeutics Market, by Cancer Type |
8.2.10.1.4. US Lung Cancer Therapeutics Market, by Distribution Channel |
8.2.10.2. Canada |
8.2.10.3. Mexico |
*Similar segmentation will be provided for each region and country |
8.3. Europe |
8.4. Asia-Pacific |
8.5. Latin America |
8.6. Middle East & Africa |
9. Competitive Landscape |
9.1. Overview of the Key Players |
9.2. Competitive Ecosystem |
9.2.1. Level of Fragmentation |
9.2.2. Market Consolidation |
9.2.3. Product Innovation |
9.3. Company Share Analysis |
9.4. Company Benchmarking Matrix |
9.4.1. Strategic Overview |
9.4.2. Product Innovations |
9.5. Start-up Ecosystem |
9.6. Strategic Competitive Insights/ Customer Imperatives |
9.7. ESG Matrix/ Sustainability Matrix |
9.8. Manufacturing Network |
9.8.1. Locations |
9.8.2. Supply Chain and Logistics |
9.8.3. Product Flexibility/Customization |
9.8.4. Digital Transformation and Connectivity |
9.8.5. Environmental and Regulatory Compliance |
9.9. Technology Readiness Level Matrix |
9.10. Technology Maturity Curve |
9.11. Buying Criteria |
10. Company Profiles |
10.1. AstraZeneca |
10.1.1. Company Overview |
10.1.2. Company Financials |
10.1.3. Product/Service Portfolio |
10.1.4. Recent Developments |
10.1.5. IMR Analysis |
*Similar information will be provided for other companies |
10.2. Pfizer Inc. |
10.3. Merck & Co., Inc. |
10.4. Roche Holding AG |
10.5. Bristol-Myers Squibb Company |
10.6. Novartis AG |
10.7. Eli Lilly and Company |
10.8. GlaxoSmithKline plc |
10.9. Bayer AG |
10.10. Sanofi |
10.11. AbbVie Inc. |
10.12. Johnson & Johnson |
10.13. Amgen Inc. |
10.14. Takeda Pharmaceutical Company Limited |
10.15. Boehringer Ingelheim |
11. Appendix |
A comprehensive market research approach was employed to gather and analyze data on the Lung Cancer Therapeutics Market. In the process, the analysis was also done to analyze the parent market and relevant adjacencies to measure the impact of them on the Lung Cancer Therapeutics Market. The research methodology encompassed both secondary and primary research techniques, ensuring the accuracy and credibility of the findings.
Secondary Research
Secondary research involved a thorough review of pertinent industry reports, journals, articles, and publications. Additionally, annual reports, press releases, and investor presentations of industry players were scrutinized to gain insights into their market positioning and strategies.
Primary Research
Primary research involved conducting in-depth interviews with industry experts, stakeholders, and market participants across the E-Waste Management ecosystem. The primary research objectives included:
- Validating findings and assumptions derived from secondary research
- Gathering qualitative and quantitative data on market trends, drivers, and challenges
- Understanding the demand-side dynamics, encompassing end-users, component manufacturers, facility providers, and service providers
- Assessing the supply-side landscape, including technological advancements and recent developments
Market Size Assessment
A combination of top-down and bottom-up approaches was utilized to analyze the overall size of the Lung Cancer Therapeutics Market. These methods were also employed to assess the size of various subsegments within the market. The market size assessment methodology encompassed the following steps:
- Identification of key industry players and relevant revenues through extensive secondary research
- Determination of the industry's supply chain and market size, in terms of value, through primary and secondary research processes
- Calculation of percentage shares, splits, and breakdowns using secondary sources and verification through primary sources
Data Triangulation
To ensure the accuracy and reliability of the market size, data triangulation was implemented. This involved cross-referencing data from various sources, including demand and supply side factors, market trends, and expert opinions. Additionally, top-down and bottom-up approaches were employed to validate the market size assessment.
NA